


Anti-TNF alpha (Infliximab), Human IgG1 Antibody

CATALOG NO:	A1097-200
ALTERNATIVE NAMES:	TNF- α ; TNF α ; TNFSF; Tumor necrosis factor; Cachectin; TNF-alpha; Tumor necrosis factor ligand superfamily member 2; TNF-a; TNF α
AMOUNT:	200 μ g
ISOTYPE / FORMAT:	Human IgG1, kappa
CLONALITY:	Monoclonal
CLONE:	cA2
SPECIES REACTIVITY:	Human
FORM:	Liquid
IMMUNOGEN:	Purified recombinant human TNF (rTNF)
SPECIFICITY:	Binds to soluble and transmembrane forms of TNF-alpha and neutralizes its biological activity. Does not bind to TNF-beta.
PURIFICATION:	Affinity purified using Protein A
FORMULATION:	Supplied in PBS with preservative (0.02% Proclin 300)
STORAGE CONDITIONS:	Store at 4°C for upto 3 months. For long term storage, aliquot and freeze at -20°C. Avoid repeated freeze/defrost cycles.
DESCRIPTION:	Recombinant monoclonal antibody to TNF alpha. Manufactured using recombinant technology with variable regions (i.e. specificity) from the therapeutic antibody cA2 (Infliximab).
BACKGROUND:	Cytokine that binds to TNFRSF1A / TNFR1 and TNFRSF1B / TNFR2. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia. Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO /SMAC mimetic in the RT4v6 bladder cancer cell line.
APPLICATION:	ELISA; in vivo; FC

REFERENCE: Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov;30 (16):1443-53.



Western Blot using anti-TNF alpha antibody: Mouse liver (lane 1), mouse spinal cord (lane 2), mouse testis (lane 3), mouse colon (lane 4) and human thyroid tumour (lane 5) samples were resolved on a 10% SDS PAGE gel and blots probed with at 1.5 μ g/ml before being detected by a secondary antibody. The expected band size (269 kDa) is seen in the human-derived samples, as well as a band corresponding to dimers.

RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), humanized Antibody (**Cat. No. A1045-100**)
- Anti-HER2 (Trastuzumab), humanized Antibody (**Cat. No. A1046-100**)
- Anti-EGFR (Cetuximab), Chimeric Antibody (**Cat. No. A1047-100**)
- Anti-TNF- α (Adalimumab), humanized Antibody (**Cat. No. A1048-100**)
- Anti-CD20 (Rituximab), Chimeric Antibody (**Cat. No. A1049-100**)
- Anti-EGFR (Panitumumab), humanized antibody (**Cat. No. A1050-100**)
- Anti-OX40L (Oxelumab), Human IgG1 Antibody (**Cat. No. A1088-200**)
- Anti-CD11a (Efalizumab), Human IgG1 Antibody (**Cat. No. A1089-200**)
- Anti-EGFR (Matuzumab), Human IgG1 Antibody (**Cat. No. A1090-200**)
- Anti-CD4 (Clenoliximab), Human IgG4 Antibody (**Cat. No. A1091-200**)
- Anti-TNF alpha (Humicade), Human IgG4 Antibody (**Cat. No. A1093-200**)
- Anti-CD40L (Ruplizumab), Human IgG1 Antibody (**Cat. No. A1094-200**)
- Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (**Cat. No. A1098-200**)

FOR RESEARCH USE ONLY! Not to be used on humans.